We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2012 by BioMimetic Therapeutics.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01746420
First Posted: December 11, 2012
Last Update Posted: December 11, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
BioMimetic Therapeutics
  Purpose
The purpose of this study is to determine whether recombinant human platelet-derived growth factor (rhPDGF-BB) Injection is effective in the treatment of lateral epicondylitis (tennis elbow).

Condition Intervention Phase
Lateral Epicondylitis Drug: rhPDGF-BB Injection Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II Randomized, Single Ascending Dose, Double-blinded, Placebo Controlled, Multi-center Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

Resource links provided by NLM:


Further study details as provided by BioMimetic Therapeutics:

Primary Outcome Measures:
  • Elbow pain [ Time Frame: 24 weeks ]
    Elbow pain as measured by the Visual Analogue Scale

  • Disability and symptoms [ Time Frame: 24 weeks ]
    Disability and symptoms measured by the Disabilities of the Arm, Shoulder, and Hand (DASH) Score

  • Pain and disability [ Time Frame: 24 weeks ]
    Pain and disability measured by the Patient Rated Tennis Elbow Evaluation (PRTEE)

  • Sincerity of effort [ Time Frame: 24 weeks ]
    Sincerity of effort measured by Grip Strength testing


Secondary Outcome Measures:
  • Adverse events [ Time Frame: 24 weeks ]
    Adverse event reporting (e.g. incidence, relationship with treatment, severity)


Estimated Enrollment: 100
Study Start Date: December 2012
Estimated Study Completion Date: March 2014
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Control
Dose A - sodium acetate buffer (0 mg rhPDGF-BB)
Drug: rhPDGF-BB Injection
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
Experimental: 0.45 mg rhPDGF-BB
Dose B - sodium acetate buffer + 0.45 mg rhPDGF-BB
Drug: rhPDGF-BB Injection
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
Experimental: 0.75 mg rhPDGF-BB
Dose C - sodium acetate buffer + 0.75 mg rhPDGF-BB
Drug: rhPDGF-BB Injection
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
Experimental: 1.5 mg rhPDGF-BB
Dose D - sodium acetate buffer + 1.5 mg rhPDGF-BB
Drug: rhPDGF-BB Injection
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
Experimental: 3.0 mg rhPDGF-BB
Dose E - sodium acetate buffer + 3.0 mg rhPDGF-BB
Drug: rhPDGF-BB Injection
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject has signed the Institutional Review Board (IRB) approved Informed Consent Form specific to this study prior to enrollment
  2. Subject has a clinical diagnosis of lateral epicondylitis
  3. Subject's symptoms can be reproduced with resisted supination or wrist dorsiflexion
  4. Subject's symptoms have persisted for at least 3 months despite conservative treatment that includes one or combinations of:

    1. Physical therapy
    2. Splinting
    3. Nonsteroidal antiinflammatory drug (NSAID)
    4. Corticosteroid injection
  5. Subject is independent, ambulatory, and can comply with all post-injection evaluations and visits
  6. Subject is 21-80 years of age and considered to be skeletally mature

Exclusion Criteria:

  1. Subject has undergone previous corticosteroid injection therapy to the effected elbow in less than three months prior to enrollment
  2. Subject has received previous Platelet Rich Plasma (PRP) injection to the affected elbow
  3. Subject is deemed to require a corticosteroid injection into the affected elbow during the course of the study
  4. Subject uses chronic medications known to affect the skeleton (e.g. glucocorticoid usage >10mg/day)
  5. Subject has undergone surgical intervention to the affected elbow for the treatment of lateral epicondylitis
  6. Subject has a positive medical history of any of the following:

    1. medial epicondylitis
    2. radial tunnel syndrome
    3. carpal tunnel syndrome
    4. septic or gouty arthritis
    5. cervical radiculopathy
    6. trauma to the affected elbow within the past 6 weeks
    7. neuromuscular or musculoskeletal deficiency, which limits the ability to perform functional measurement (e.g. grip strength test)
  7. Subject currently has an acute infection at the injection site
  8. Subject has tested positive or been treated for a malignancy in the past or is suspected of having a malignancy or are currently undergoing radio- or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed rhPDGF-BB Injection treatment site
  9. Subject is physically or mentally compromised (e.g. currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant
  10. Subject has an allergy to yeast-derived products
  11. Subject has received an investigational therapy or approved therapy for investigational use within 30 days of injection procedure or during the follow-up phase of this study
  12. Subject is a prisoner, or is known or suspected to be transient
  13. Subject's condition represents a worker's compensation case
  14. Subject is currently involved in a health-related litigation procedure
  15. Subject has documented evidence of a history (e.g. liver testing) of drug/alcohol abuse within the 12 months prior to screening for study entry
  16. Subject is pregnant, or able to become pregnant but not practicing a medically-accepted form of birth control, and/or intending to become pregnant during this study period
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01746420


Locations
United States, Arizona
Arizona Research Center Recruiting
Phoenix, Arizona, United States, 85023
Contact: Maria Hill    602-773-3019    mhill@azresearchcenter.com   
Principal Investigator: Joseph Gimbel, MD         
Sub-Investigator: Louise Taber, MD         
Tucson Orthopaedic Institute Recruiting
Tucson, Arizona, United States, 85712
Contact: Jelena Candito    520-784-6466    jcandito@tucsonortho.com   
Principal Investigator: Nebojsa Skrepnik, MD, PhD         
Sub-Investigator: Brian Nielsen, MD         
Sub-Investigator: Joel Goode, MD         
Sub-Investigator: Andrew Mahoney, MD         
Sponsors and Collaborators
BioMimetic Therapeutics
Investigators
Principal Investigator: Edward Akelman, MD Brown University
  More Information

Responsible Party: BioMimetic Therapeutics
ClinicalTrials.gov Identifier: NCT01746420     History of Changes
Other Study ID Numbers: BMTI-2010-02
First Submitted: December 7, 2012
First Posted: December 11, 2012
Last Update Posted: December 11, 2012
Last Verified: December 2012

Keywords provided by BioMimetic Therapeutics:
elbow

Additional relevant MeSH terms:
Tennis Elbow
Elbow Tendinopathy
Tendinopathy
Muscular Diseases
Musculoskeletal Diseases
Arm Injuries
Wounds and Injuries
Tendon Injuries
Becaplermin
Angiogenesis Inducing Agents
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs